You just read:

Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD

News provided by

Medivir

Nov 01, 2010, 02:00 ET